Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Stuttgart - Delayed Quote EUR

Sanofi SA (SNW.SG)

92.72
-1.17
(-1.25%)
As of 2:00:08 PM GMT+2. Market Open.
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
44,286,000
44,286,000
41,618,000
40,561,000
39,175,000
Cost of Revenue
13,205,000
13,205,000
12,628,000
11,882,000
12,255,000
Gross Profit
31,081,000
31,081,000
28,990,000
28,679,000
26,920,000
Operating Expense
21,619,000
21,619,000
19,815,000
17,753,000
17,773,000
Operating Income
9,462,000
9,462,000
9,175,000
10,926,000
9,147,000
Net Non Operating Interest Income Expense
-560,000
-560,000
-706,000
-223,000
-370,000
Other Income Expense
-2,204,000
-2,204,000
-2,218,000
-766,000
-979,000
Pretax Income
6,698,000
6,698,000
6,251,000
9,937,000
7,798,000
Tax Provision
1,204,000
1,204,000
1,017,000
1,909,000
1,558,000
Earnings from Equity Interest Net of Tax
60,000
60,000
-136,000
55,000
39,000
Net Income Common Stockholders
5,560,000
5,560,000
5,400,000
8,371,000
6,223,000
Diluted NI Available to Com Stockholders
5,560,000
5,560,000
5,400,000
8,371,000
6,223,000
Basic EPS
4.44
4.44
4.31
6.69
4.97
Diluted EPS
4.43
4.43
4.30
6.66
4.97
Basic Average Shares
1,251,400
1,251,400
1,251,700
1,251,900
1,252,500
Diluted Average Shares
1,256,100
1,256,100
1,256,400
1,256,900
1,252,500
Total Operating Income as Reported
7,252,000
7,252,000
6,960,000
10,162,000
8,126,000
Total Expenses
34,824,000
34,824,000
32,443,000
29,635,000
30,028,000
Net Income from Continuing & Discontinued Operation
5,560,000
5,560,000
5,400,000
8,371,000
6,223,000
Normalized Income
7,303,280
7,303,280
6,918,466
8,588,928
7,006,400.87
Interest Income
413,000
413,000
527,000
239,000
3,000
Interest Expense
749,000
749,000
710,000
465,000
389,000
Net Interest Income
-560,000
-560,000
-706,000
-223,000
-370,000
EBIT
7,447,000
7,447,000
6,961,000
10,402,000
8,187,000
EBITDA
11,033,000
11,033,000
11,390,000
13,510,000
11,538,000
Reconciled Cost of Revenue
11,368,000
11,368,000
10,110,000
10,578,000
10,484,000
Reconciled Depreciation
3,586,000
3,586,000
4,429,000
3,108,000
3,351,000
Net Income from Continuing Operation Net Minority Interest
5,496,000
5,496,000
5,062,000
7,970,000
6,223,000
Total Unusual Items Excluding Goodwill
-2,204,000
-2,204,000
-2,218,000
-766,000
-979,000
Total Unusual Items
-2,204,000
-2,204,000
-2,218,000
-766,000
-979,000
Normalized EBITDA
13,237,000
13,237,000
13,608,000
14,276,000
12,517,000
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-396,720
-396,720
-361,534
-147,072
-195,599.13
12/31/2021 - 12/28/2007

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

GIS.HM Gilead Sciences Inc
90.01
-4.70%
 
REC.MI Recordati Industria Chimica e Farmaceutica S.p.A.
49.60
+0.77%
 
NOVN.SW Novartis AG
92.67
+0.73%
 
AZN.L AstraZeneca PLC
10,458.00
+0.13%
 
AZN AstraZeneca PLC
69.55
+1.52%
 
NOVO-B.CO Novo Nordisk A/S
399.55
-2.57%
 
ABBV AbbVie Inc.
180.37
+1.88%
 
BMY Bristol-Myers Squibb Company
48.69
+0.33%
 
JNJ Johnson & Johnson
154.93
-0.29%
 
MRK Merck & Co., Inc.
79.84
+1.40%